Suppr超能文献

唑吡坦治疗神经外科手术后局灶性肌张力障碍的疗效与安全性:一项回顾性队列研究

Efficacy and Safety of Zolpidem for Focal Dystonia After Neurosurgical Treatments: A Retrospective Cohort Study.

作者信息

Horisawa Shiro, Kohara Kotaro, Ebise Hiroki, Nishitani Masahiko, Kawamata Takakazu, Taira Takaomi

机构信息

Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.

出版信息

Front Neurol. 2022 May 3;13:837023. doi: 10.3389/fneur.2022.837023. eCollection 2022.

Abstract

Although there are several reports of the significant efficacy of zolpidem for treating dystonia, zolpidem is still considered an anecdotal treatment. Here, we evaluated the efficacy and safety of zolpidem for treating residual dystonia in patients who previously received various neurosurgical treatments majorly including deep brain stimulation and radiofrequency ablation. We retrospectively reviewed medical records from January 2021 to September 2021 to identify patients with dystonia who had been prescribed zolpidem after undergoing neurosurgery. Twenty patients were enrolled in this study, including those with blepharospasm (two), tongue dystonia (four), mouth dystonia (one), spasmodic dysphonia (two), cervical dystonia (six), focal hand dystonia (three), hemidystonia (two), blepharospasm with cervical dystonia (one), and mouth dystonia with cervical dystonia (one). Single doses of zolpidem ranged between 2.5 and 10 mg, while daily dosages ranged from 10 to 30 mg. The zolpidem dose prescribed was 5-10 mg, with single and daily doses of 7 ± 2.9 and 14.5 ± 6.0 mg, respectively. With zolpidem administration, the participants' Burke-Fahn-Marsden Dystonia Rating Scale-Movement Scale score significantly improved from 8.1 ± 6.7 to 3.7 ± 2.5 (50.6% improvement, < 0.0001). Improvements in arm dystonia, blepharospasm, and spasmodic dysphonia were observed using the Arm Dystonia Disability Scale, Jankovic Rating Scale, and Voice Handicap Index, respectively. No improvements were observed in cervical dystonia on the Toronto Western Spasmodic Torticollis Rating Scale. Drowsiness, including three cases each of mild and moderate drowsiness, was the most frequent adverse effect (30%), which persisted for 2-3 h. Transient amnesia and rapid eye movement sleep behavior disorder occurred in two patients and one patient, respectively. Although our findings suggest that zolpidem can be a valuable treatment option for patients with residual dystonia after neurosurgical treatments, the beneficial effects for cervical dystonia were limited.

摘要

尽管有几份关于唑吡坦治疗肌张力障碍疗效显著的报告,但唑吡坦仍被视为一种经验性治疗方法。在此,我们评估了唑吡坦对先前接受过包括脑深部电刺激和射频消融等各种神经外科治疗的患者残留肌张力障碍的疗效和安全性。我们回顾性分析了2021年1月至2021年9月的病历,以确定神经外科手术后服用唑吡坦的肌张力障碍患者。本研究共纳入20例患者,包括眼睑痉挛患者(2例)、舌肌张力障碍患者(4例)、口肌张力障碍患者(1例)、痉挛性发音障碍患者(2例)、颈部肌张力障碍患者(6例)、手部局灶性肌张力障碍患者(3例)、偏侧肌张力障碍患者(2例)、眼睑痉挛合并颈部肌张力障碍患者(1例)以及口肌张力障碍合并颈部肌张力障碍患者(1例)。唑吡坦单次剂量在2.5至10毫克之间,每日剂量在10至30毫克之间。所开的唑吡坦剂量为5至10毫克,单次和每日剂量分别为7±2.9毫克和14.5±6.0毫克。服用唑吡坦后,参与者的伯克-法恩-马斯登肌张力障碍评定量表-运动量表评分从8.1±6.7显著提高到3.7±2.5(改善50.6%,<0.0001)。分别使用手臂肌张力障碍残疾量表、扬科维奇评定量表和嗓音障碍指数观察到手臂肌张力障碍、眼睑痉挛和痉挛性发音障碍的改善。在多伦多西部痉挛性斜颈评定量表上,颈部肌张力障碍未观察到改善。嗜睡是最常见的不良反应(30%),包括轻度和中度嗜睡各3例,持续2至3小时。两名患者分别出现短暂性失忆和快速眼动睡眠行为障碍,一名患者出现快速眼动睡眠行为障碍。尽管我们的研究结果表明唑吡坦可能是神经外科治疗后残留肌张力障碍患者的一种有价值的治疗选择,但对颈部肌张力障碍的有益作用有限。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b2ec/9111172/635f69cc50ac/fneur-13-837023-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验